# ADAURA2 (NCT05120349)

> A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05120349
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Non-Small Cell Lung Cancer
- Interventions: Osimertinib; Placebo
- Enrollment: 390
- Primary outcome: Disease-Free Survival (DFS) in high-risk stratum

## Commentary we found

- YouTube: 13
- Podcasts: 10
- X threads: 4

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=adaura2-nct05120349

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05120349", "email": "<work email>"}; the inbox owner confirms by the emailed link.